Howard Scher, MD
Enriched profileEmeritus Faculty Member; founding Head of the Biomarker Development Program; holds the D. Wayne Calloway Chair in Urologic Oncology (former Chief of the Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, for 25 years) · Memorial Sloan Kettering Cancer Center
Howard Scher is Emeritus Faculty Member; founding Head of the Biomarker Development Program; holds the D. Wayne Calloway Chair in Urologic Oncology (former Chief of the Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, for 25 years) at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,431 publications with 133,670 citations (h-index 164); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Howard Scher as a Highly Cited Researcher (Clinical Medicine, 2014-2021; Cross-Field, 2022).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Howard I. Scher, MD, is Emeritus Faculty Member at Memorial Sloan Kettering Cancer Center, New York, NY. The public record shows 1,431 publications with 133,670 citations (h-index 164), centered on Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 9 companies, 4 NIH-funded awards (1999–2025).
- Most recent indexed publication: 2026 · Nature reviews. Urology
- Top research focus: Prostate Cancer Treatment and Research
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 628.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Sponsor: Memorial Sloan Kettering Cancer Center
- Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20256 payments$13,212openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Gonadotropin Releasing Hormone Receptor Antagonist55.8%Orgovyx100%Part D<11 patientsAnti-androgens44.2%Nubeqa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 1999–2025 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.
Nature reviews. Urology
Review2026 - Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Clinical cancer research
Clinical Trial2026 - Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis.
Clinical pharmacology and therapeutics
Review2025
Most-cited works
by citation count (OpenAlex)- 01Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy4,583 citations2012
- 02Abiraterone and Increased Survival in Metastatic Prostate Cancer4,400 citations2011
- 03
- 04Integrative Genomic Profiling of Human Prostate Cancer3,792 citations2010
- 05Integrative Clinical Genomics of Advanced Prostate Cancer3,652 citations2015
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/howard-scher-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/howard-i-scher-md-0726548
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
en.wikipedia.org/wiki/Howard_Scher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Mentions by others
where others cite or feature them- LinkedIn
LinkedIn profile: Howard I. Scher, MD - Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Synapse.mskcc.org
MSK Synapse profile page referencing Howard Scher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synapse.mskcc.org ↗ - Pcf.org
Prostate Cancer Foundation researcher profile referencing Howard Scher
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pcf.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bates.edu ↗
- MD
New York University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Residency
Internal Medicine, Bellevue Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Board-certified
Internal Medicine and Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - BS
Bates College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Editorial & leadership roles
journal and society appointments- Founding Head
Biomarker Development Program, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Principal Investigator
MSK Prostate Cancer SPORE (NCI-sponsored)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Member
Prostate Cancer Clinical Trials Consortium (PCCTC); led international effort to standardize phase 2 trial design/conduct/analysis in prostate cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pcctc.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine20142015201620172018201920202021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- American Association for Cancer Research (AACR) Team Science Award
2015, 'Designing AR Inhibitors Team' (shared with Michael E. Jung and Charles Sawyers, for discovery/development of enzalutamide and ARN-509)
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College (Joan & Sanford I. Weill Medical College of Cornell University)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗ - Co-Chair
Center for Mechanism-Based Therapy, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rocketreach.co ↗ - Professor of Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center